News | February 23, 2022
Complement Therapeutics raises €5 million seed financing
Appoints Dr Rafiq Hasan as CEO
Appoints Dr Rafiq Hasan as CEO
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
The SureSTART consumables portfolio is designed for higher performance requirements, while meeting customer budgets
US $ 555,000 invested by Wavemaker Partners in pre-seed round
The transaction as well as the open offer is expected to be completed by June this year.
The sale is expected to close in the first quarter of 2022
By connecting a leading LongBio VC to the DeSci (decentralized science) movement, this partnership is a major milestone for the greater decentralized ecosystem
The researchers are of the view that the new drug designing strategy demonstrated by them could also be adopted to treat retroviral infections.
According to the Indian Journal of Medical Research in 2018, the estimated prevalence of pre-diabetes in India is 14%, which means that one out of six Indians is pre-diabetic
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
Subscribe To Our Newsletter & Stay Updated
